Quizartinib ≥95%
Supplier: ADIPOGEN CORP MS
|
Warning
|
Synonyms:
AC220, 1-(5-(tert-Butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea
Quizartinib (AC220) is a second-generation FLT3 inhibitor that has shown promising activity in AML in Phase II clinical trials. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Recently, AC220 has also been shown to be an effective inhibitor of ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5µM and from 0.5 to 10µM, respectively, and inhibited-IAAP photolabeling of ABCG2 and ABCB1 with IC(50) values of 0.07 and 3.3µM, respectively.
Formula:
C₂₉H₃₂N₆O₄S MW: 560.7 g/mol Storage Temperature: Freezer |
MDL Number:
MFCD18074524 CAS Number: 950769-58-1 |
Specification Test Results
Purity |
|
Appearance/Color | Solid. |
Solubility |
Soluble in DMSO. Slightly soluble ( |
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...